---
schema_version: "secwatch.filing_event.v1"
accession: "0002070849-26-000048"
form_type: "8-K"
ticker: "BLLN"
cik: "0002070849"
company_name: "BillionToOne, Inc."
filed_at: "2026-08-05T20:25:27+00:00"
generated_at: "2026-08-05T20:26:07.852608+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BillionToOne Q2 revenue $109.4M (+64% YoY); net income $8.1M; reiterates FY guidance $450-465M

## Summary
- Revenue $109.4M (+64% YoY); prenatal $94.2M (+55%), oncology $13.7M (+176%).
- Gross margin 70% (vs 65%); operating income $5.5M vs loss of $1.6M; net income $8.1M ($0.15 EPS).
- 196,000 tests delivered (+35%); free cash flow $5.1M.
- Reiterates FY2026 revenue guidance $450M-$465M (48-52% growth).
- Announces expanded Unity Fetal Risk Screen (130-gene panel) and Northstar Origin launch.

## SEC filing metadata
- accession: 0002070849-26-000048
- form_type: 8-K
- ticker: BLLN
- cik: 0002070849
- company_name: BillionToOne, Inc.
- filed_at: 2026-08-05T20:25:27+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2070849/000207084926000048/0002070849-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2070849/000207084926000048/blln-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002070849-26-000048
- JSON: https://secwatch.observer/filing/0002070849-26-000048.json
- Plain text: https://secwatch.observer/filing/0002070849-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.